Antelope Therapeutics

Edouard LEROY is flying to San Diego in a few days for #BIO2026, as part the French delegation alongside Business France North America and the French Healthcare Association. He'll meet with investors and pharma partners to accelerate the development of ATL-024, Antelope's innovative CA242-targeting ADC for the treatment of GI cancers. Thank you to Région Auvergne-Rhône-Alpes and Lyonbiopôle Auvergne-Rhône-Alpes for their support in enabling our participation in this major partnering convention. #LifeSciences #Biotech #Pharma #BusinessFrance #AntelopeTx #Licensing #ChooseFrance #FrenchHealthcare

Yesterday, we presented a poster summarizing the key data of ATL-024, our CA242-targeting ADC for the treatment of colorectal, pancreatic and gastric cancer. It was energizing to feel so much interest from the drug development community! Here is a picture of Warren Viricel in front of our poster, just before the launch of the poster session. Edouard LEROY and Warren were busy for the next 3 hours, fielding questions from scientists and investors. #AACR2026 #ADC

Beyond the 28% ORR Ceiling: Why CRC Needs a New Generation of ADCs. The Colorectal Cancer (CRC) landscape is evolving rapidly. With one ADC against cMET offering great promise for 25% of the patients, and several others targeting CEACAM5, CDH17, and EpCAM, the industry is making strides. However, looking at the data, a clear challenge remains. While these 3 targets cover a large patient population on paper, clinical results disclosed so far have largely plateaued, remaining below a 28% ORR. For patients with CRC cancers, there is still significant unmet therapeutic potential. At Antelope Therapeutics, we believe the answer lies in combining a first-in-class target with a superior ADC architecture. Our lead candidate, ATL-024, is designed to move the needle: 🔹 Unique Differentiation: Unlike the crowded CEACAM5 or CDH17 space, ATL-024 hits a novel target with a distinct expression profile and a new ADC design. 🔹 Proven Potency: In a 16 CRC SMT-PDX model study, ATL-024 demonstrated compelling efficacy, outperforming current benchmarks. 🔹 Safety First: We have achieved the highest HNSTD (Highest Non-Severely Toxic Dose) ever disclosed for a CRC ADC, providing the wide therapeutic window necessary for clinical success. We aren't just adding to the list of CRC targets; we are aiming to redefine what "efficacy" looks like for these patients. Join us at #AACR26 in San Diego: We will be presenting our preclinical data set and would welcome the opportunity to dive into the science with you. 📍 Poster Number: #15 (Abstract 3180) 📍 Section 19 📍 Session: PO.ET01.06 🗓️ April 20, 2-5pm (PST) 🔴 Strategic Discussions: As we prepare for IND-enabling activities, we are open to strategic discussions with pharma and biotech partners looking to strengthen their GI oncology pipeline with a truly differentiated asset. Let’s accelerate the development of ATL-024 together. DM Edouard LEROY or Warren Viricel to schedule a meeting on-site. #Oncology #ADC #GICancer #Biotech #ClinicalDevelopment #AntelopeTx

The data is out: our first-in-class ADC, ATL-024, will be featured at the upcoming AACR Annual Meeting in San Diego! Following our recent launch, we are excited to share the scientific foundation of Antelope Therapeutics. The public abstract for our poster presentation is now available (link in the comment), highlighting the preclinical performance of ATL-024 in gastrointestinal cancers. Key takeaways from our findings include: 🔹 Best-in-disease potential: ATL-024 demonstrated a compelling efficacy in multiple models, including in a 16 CRC models SMT-PDX study. The tolerability in NHP was also outstanding with the highest HNSTD ever disclosed for CRC ADCs. 🔹 Broad GI applicability: Robust efficacy was observed not only in CRC but also in Pancreatic and Gastric cancer models. At Antelope, we are building a solution for patients with high unmet needs in GI oncology. We look forward to discussing these results and our path toward the clinic with the global scientific, pharma and investment community. See you at the poster! #Oncology #AACR26 #ADC #GICancer #Biotech #DrugDiscovery #AntelopeTx